Lisata Therapeutics Inc.

2.55
-0.06 (-2.30%)
At close: Feb 11, 2025, 3:58 PM
2.51
-1.57%
After-hours Feb 11, 2025, 04:04 PM EST
undefined%
Bid 2.45
Market Cap 21.41M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -2.51
PE Ratio (ttm) -1.02
Forward PE n/a
Analyst Buy
Ask 2.95
Volume 13,830
Avg. Volume (20D) 43,445
Open 2.55
Previous Close 2.61
Day's Range 2.47 - 2.62
52-Week Range 2.19 - 4.20
Beta undefined

About LSTA

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfun...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 1, 1999
Employees 25
Stock Exchange NASDAQ
Ticker Symbol LSTA

Analyst Forecast

According to 1 analyst ratings, the average rating for LSTA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 488.24% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
2 weeks ago
-29.49%
Lisata Therapeutics shares are trading lower after... Unlock content with Pro Subscription
4 months ago
+6.53%
Lisata Therapeutics shares are trading higher after the company announced its first patient was treated in the second-line cholangiocarcinoma cohort of the BOLSTER trial.